# Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Source: https://onco.cc/trials/nct06467357/  
OnCo record `nct06467357` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan and Rilvegostomig in biliary tract cancer, run by AstraZeneca, now recruiting.

## Summary

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer is a phase 3 interventional study registered as NCT06467357 by AstraZeneca, with 620 participants planned, started 2024-08-12 and due to reach its primary completion in 2028-06-12. Interventions recorded: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan and Rilvegostomig.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06467357
- Phase: 3
- Setting: DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
- Sponsor: AstraZeneca
- Enrolled: 620

## Sources

- ClinicalTrials.gov NCT06467357: https://clinicaltrials.gov/study/NCT06467357

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06467357.json